Abstract. The transcription factor Ikaros was originally found to function as a key regulator of lymphocyte differentiation. In this study, we provide the first evidence that Ikaros is expressed at higher levels in ovarian cancer tissues compared with normal ovarian tissues and is significantly associated with high FIGO stage and low differentiation state in ovarian serous adenocarcinoma. To this end, we transfected IK1 (full length of Ikaros) into the SKOV3 ovarian cancer cell line and examined cell biological behaviors including proliferation, migration and invasion. We found that overexpression of IK1 inhibited cell proliferation by inducing G 1 arrest, accompanied by the upregulation of P27 and P21 and downregulation of cyclin D1 and D2. On the other hand, IK1 increased the migration and invasion of ovarian cancer cells, as assessed by scratch-wound assay, transwell migration assay, and invasion assay. Overexpression of IK1 significantly increased Slug but not Snail1 expression at both mRNA and protein levels. It also downregulated and upregulated E-cadherin and MMP-2, two target genes of Slug involved in migration, respectively. Furthermore, knocking down Slug abrogated IK1-mediated increase in migration and invasion. These data suggest that Slug plays an important role in IK1-induced migration and invasion. In conclusion, we show for the first time that IK1 plays a dual role in the proliferation, migration and invasion of ovarian cancer cells, providing new insights into their metastasis.
Introduction
Ovarian cancer is one of the most common gynecological malignancies and the leading cause of death from gynecological cancers in women (1) . Despite considerable efforts to improve early detection and the advances in chemotherapy, metastasis remains a major challenge in the clinical management of ovarian cancer. Approximately 70% of patients present with tumors that have spread beyond the ovaries (2) . However, the mechanism through which a primary ovarian cancer cell develops into a metastatic phenotype is not well understood.
Ikaros, a member of a family of zinc finger transcription factors, is encoded by the IKZF1 gene (also known as ZNFN1A1) that comprises 8 exons. Alternative splicing of exons 3-6 can generate multiple Ikaros isoforms (3, 4) . Ikaros was originally found to function as a critical regulator of lymphocyte differentiation. Subsequent studies reported that Ikaros also plays a role in hematopoietic stem cells and some myeloid cells (5) (6) (7) (8) . Moreover, Ikaros has also been shown to be expressed in mouse pituitary tissues, where it regulates the expression of adrenocorticotropic hormone and the adrenocortical hormone output (9) , and several other tissues including liver, lung, prostate, brain, heart, placenta and intestine, in which the role of Ikaros is largely unknown. A recent report showed that the expression of Ikaros was correlated with the prognosis of several kinds of cancers including breast, lung, ovarian and skin cancers (10) , suggesting a possible role of Ikaros in solid tumors. However, the expression and functional role of Ikaros in ovarian cancer have not been well studied. In this study, through immunohistochemical analysis, we found that Ikaros is expressed at higher levels in human ovarian cancer tissues than normal ovarian tissues, and Ikaros expression level is correlated with the different stages of ovarian serous adenocarcinoma cancer. Furthermore, we demonstrated that Ikaros may perform a dual role in ovarian cancer cells, that is, inhibiting cell proliferation and enhancing cell migration and invasion. We show that Slug (also known as Snail 2), an epithelial-mesenchymal transition associated protein, plays an important role in Ikaros-induced migration and invasion in ovarian cancer cells.
Ikaros inhibits proliferation and, through upregulation of Slug, increases metastatic ability of ovarian serous adenocarcinoma cells

Materials and methods
Cell cultures. Human epithelial ovarian cancer cell line SKOV3 was obtained from ATCC (Manassas, VA). SKOV3 and HEK293T cell lines were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO) or Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, Gibco BRL, Gaithersburg, MD). All cell lines were incubated in a 5% CO 2 /95% air humidified atmosphere at 37˚C.
Retrovirus production and transduction of target cells.
The pMSCV-puro-Flag-IK1 plasmid was obtained as reported previously (11) . To produce virus, pGag-pol and pVSVG (Clontech, Palo Alto, CA) were co-transfected with pMSCV-puro-Ikaros or vehicle plasmid into 293T using FuGENE6 (Roche Applied Science, Basel, Switzerland) according to the manufacturer's instructions. Retrovirus-containing supernatant was harvested 48 h after transfection. The day before retrovirus infection, 3x10 5 cells were seeded in 2 ml growth medium. On the next day, the growth medium was aspirated from the plate, 0.5 ml growth medium was added, and 2 ml retrovirus-containing supernatant was mixed with polybrene (Sigma, St. Louis, MO) to a final concentration of 2 µg/ml. Forty-eight hours later, 1 µg/ ml puromycin (Sigma) was added to the medium. Positive polyclone population was identified based on Flag-IK1 expression.
Quantitative real-time polymerase chain reaction. Total cellular RNA was extracted by TRIzol kit (Invitrogen), followed by treatment with RNase-free DNase (Promega, Madison, WI). Complementary DNA was synthesized according to the manufacturer's instructions (Promega). Fluorescence real-time quantitative RT-PCR was performed with the double-stranded DNA dye SYBR Green PCR Core Reagents (PE Biosystems, Warrington, UK) using the ABI PRISM 7900 system (PerkinElmer, Torrance, CA). The specific primers used are shown in Table I . Real-time quantitative RT-PCR was performed and data were analyzed according to a previous report (12) .
Tissue microarrays and immunohistochemistry. An ovarian cancer tissue array (US Biomax Inc., Rockville, MD) containing ovarian tumors from 87 patients and 10 cases of normal tissues were used for this study. Deparaffinization and antigen retrieval were accomplished by using Trilogy solution (Cell Marque, Rocklin, CA) and heating/pressure supplied by a conventional pressure cooker. Endogenous peroxidase activity was inhibited by using 0.3% hydrogen peroxide. Nonspecific interactions were blocked by using normal goat serum. Ikaros antibody (ab26083, Abcam) was diluted (1:100) in PBS and incubated at 4˚C overnight. Bound antibody was detected by using biotin-linked anti-rabbit secondary antibody and streptavidin-conjugated HRP enzyme in conjunction with DAB chromagen. Tissue was counterstained with hematoxylin. The immunoreactivity was defined by discrete brownish chromogen deposit in the cells. To quantify Ikaros expression, we further analyzed the cases with Ikaros expression by IPP (Image-Pro Plus, version 5.0, Media Cybernetics, Silver Spring, MD) using a method introduced by Xavier et al (13) .
Cell proliferation assay. Cell proliferation was determined by Cell Counting kit-8 assay (Dojindo, Japan), a sensitive nonradioactive colorimetric assay for determining cell growth, according to the manufacturer's instructions.
Cell cycle analysis. Briefly, Cells were fixed in 75% ethanol, resuspended in staining solution containing 50 µg/ml propidium iodide (PI) and 100 µg/ml RNase A, and incubated at 37˚C for 30 min. DNA content was analyzed by flow cytometry on a FACScan (Becton-Dickinson).
Scratch-wound assay. Cells were seeded to form a monolayer on 6-well plate surface and then a scratch wound was performed by dragging a sterile pipette tip across the layer. Detached cells were washed away with cell culture medium. An image was captured immediately by Olympus BX51 fluorescence microscope and the wound distance was calculated as a basic width. After 24 h, cells were washed 3 times by PBS and another image was taken and the width of the wound distance was calculated. The wound closure (%) was determined as the width migrated after 24 h relative to the basic width.
Transwell migration and invasion assay. Cell migration and invasion were gauged using a transwell migration assay and a matrigel invasion assay. Cell migration was examined using transwell chamber assay according to the protocol of the manufacturer (Costar). Briefly, 2.0x10 5 cells in RPMI-1640 plus 1% FBS in 200 µl of RPMI-1640 were placed on each 8.0-µm pore size upper chamber. RPMI-1640 plus 10% FBS was placed in the bottom wells as chemoattractant. The invasion assay used a BD Biocoatt Matrigelt Invasion Chamber (BD Biosciences, Bedford, MA, USA) with an 8.0-µm pore size polyethylene terephthalate (PET) membrane coated with matrigel. The inserts were rehydrated by adding 0.5 ml of warm culture medium at 37˚C for 2 h. The cells were seeded (2.0x10 5 cells in 0.5 ml of serum-free medium) in the upper chamber and cultured as described in the method for the migration assay. After 24 h, the nonmigrated or noninvaded cells on top of the membrane were gently removed with a cotton swab. Cells that had migrated or invaded were stained with 0.1% crystal violet (Sigma) and were counted and photographed under a microscope at a magnification of 400 in five to six randomly selected areas.
Western blot analysis. Western blotting was performed as previously described (11) . Antibodies for western blotting are anti-Slug (9585), anti-Snail1 (3879), anti-β-catenin (9582), anti-P21 (2947), anti-cyclin D1 (2922) from Cell Signaling, anti-P27 (Santa Cruz, SC-528), anti-flag (F1804, Sigma), anti-Ikaros (ab26083, Abcam), anti-β-actin (CP01, Calbiochem), and anti-β-tubulin (T4026, Sigma). All experiments were repeated at least three times.
RNA interference and transfection. All RNAi oligonucleotides were chemically synthesized by GenePharma Co. (Shanghai, China). These RNAi oligonucleotides were transfected into cells by using the Lipofectamine 2000 transfection kit (Invitrogen) according to the manufacturer's instructions. The siRNA sequences were as follows: nonspecific control (NC) 5'-UUCUCCGAACGUGUCACGU-3', Slug-1 siRNA human (S1) 5'-GGACUACCGCUGCUCCAUU-3', Slug-2 siRNA human (S2) 5'-GACCCACACAUUACCUUGU-3' and Slug-3 siRNA human (S3) 5'-GCACAAACAUGAGGAAUCU-3'.
Statistical analysis. The χ 2 test was applied to test for a possible association between Ikaros expression and histological grade and type. Kruskal-Wallis test was performed to examine the significance of Ikaros expression among the groups as determined by IPP. Student's t-test was used to evaluate the difference between two different groups. All statistical analyses were performed using the SPSS software package (version 17.0, SPSS, Inc., Chicago, IL). Tests were 2-sided and P<0.05 was considered as statistically significant.
Results
Ikaros is expressed at high levels in human ovarian cancer tissues. To evaluate the expression levels of Ikaros in ovarian cancer, immunohistochemistry was performed on tissues from 87 cases of ovarian cancer and 10 cases of normal (only intact tissue samples were included). Compared with the weak positive staining of IK1 observed in 10% (1/10) of normal ovarian tissues, significant increase of positive staining of IK1 in 71% (62/87) of ovarian cancer were observed (Table II, P<0.001).
We further analyzed the 10 normal ovarian tissues and 58 specimens of ovarian serous adenocarcinoma (OSA) tissues. The latter represents the most common subtype of epithelial ovarian cancer. Representative immunohistochemical findings of IK1 in tissue specimens are shown in Fig. 1 . Significantly higher expression of IK1 was observed in malignant cancer tissues than in normal ovarian tissues and significant differences were also observed among different pathology grades (Table III, P<0.001 and Fig. 1A ) and clinical stages of OSA (Table III, ) or the empty vector (SKOV3 EV ). As shown in Fig. 2A , significant cell proliferation inhibition was observed in SKOV3
Flag-IK1 cells compared with SKOV3 EV cells. In addition, IK1 overexpression elicited a significant increase in the number of SKOV3 cells in the G 0 /G 1 phase with a concomitant decline in the S and G 2 /M phases (Fig. 2B) . Consistent with the G 1 -arrest phenotype, SKOV3
Flag-IK1 cells showed a dramatic elevation in the expression of the cell cycle inhibitors (14,15), P21 and P27, along with a substantial decrease in the expression of the cell cycle inducers (16, 17) , cyclin D1 and D2 (Fig. 2C) . Similar results were observed in another OSA cell line HO8910 (data not shown), indicating that IK1-induced inhibition of cell proliferation is not SKOV3 cell specific.
Overexpression of IK1 enhances migration and invasion of OSA cells.
Since tissues analysis suggested that IK1 expression is associated with progression of ovarian cancer, we next investigated the effect of IK1 on the metastasis of ovarian cancer. The scratch wound healing assay (Fig. 3A) , and transwell chamber assays (Fig. 3C) and D). Similar results were also observed in HO8910 cells (data not shown).
IOD ----------------------------------------------------------
IK1 overexpression influences expression of metastasisrelated genes.
To investigate how IK1 affects the metastatic process, a series of metastasis-related genes including Snail1, Slug, β-catenin, E-cadherin, N-cadherin, matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) were examined in SKOV3 Flag-IK1 and SKOV3 EV cells. At mRNA level, overexpression of IK1 in SKOV3 cells resulted in a significant increase in the expression of Slug and MMP-2 and a significant decrease of E-cadherin. A slight downregulation of β-catenin was also observed (Fig. 3E) . At the protein level, overexpression of IK1 in SKOV3 cells resulted in a marked increase of Slug and a decrease of β-catenin (Fig. 3F) . Similar results were also observed in HO8910 cells (data not shown). These results indicated a potential role for Slug in IK1-induced migration and invasion of OSA cells.
Slug is responsible for IK1-induced migration and invasion of OSA cells.
To illustrate whether Slug mediates IK1-induced migration and invasion of ovarian cancer, Slug was specifically knocked down by RNA interference. As shown in Fig. 4A , the target sequence S1 and S3 against Slug were efficient and specific, as the expression of Slug was efficiently suppressed with no effect on IK1 expression. Next, nonspecific control vector (NC) and S3 were transiently transfected into SKOV3
Flag-IK1 cells. Seventy-two hours after transfection, the scratch wound healing assay (Fig. 4B) , traswell migration assay, and matrigel invasion assay (Fig. 4D) were performed. The results revealed that the suppression of Slug expression could significantly block IK1-induced migration and invasion of SKOV3
Flag-IK1 cells ( Fig. 4C and E) . These results indicated that Slug contributed to IK1-induced cell migration and invasion in ovarian cancer cells.
Discussion
The ability to metastasize makes ovarian cancer a fatal disease and a significant number of patients treated for the localized disease ultimately present with metastases. A better understanding of molecular events that contribute to tumor invasion and metastasis is crucial for developing novel treatment strategies for ovarian cancer.
Although most studies on Ikaros are restricted to the hematopoietic system, Ikaros plays a role in other tissues (9, (18) (19) (20) (21) . In this study, we show for the first time that Ikaros is involved in the metastasis and invasion of ovarian cancer cells. First, higher expression of IK1 was observed in malignant ovarian cancer tissues and was significantly associated with the high FIGO stage and low differentiation state in OSA; second, overexpression of IK1 in OSA cells resulted in enhanced cell invasion and metastasis. Consistent with our results, Yamamoto et al (19) reported that IK1 is involved in migration and invasion of extravillous trophoblasts in early placentation, although the underlying mechanism is unknown.
Slug is a member of the Snail family of zinc finger transcription factors that play a central role in the patterning of vertebrate (22) . Recent evidence showed that Slug is upregulated in metastatic breast cancer, mesothelioma, and ovarian cancer, and plays an important role in cancer invasion (23, 24) . It is interesting to note that Slug is also implicated in IK1-induced cell migration and invasion. While IK1 significantly upregulated the expression of Slug, knocking down Slug abrogated IK1-induced cell migration and invasion. It is known that Slug could regulate the cell metastasis and invasion through regulation of the expression of junctional proteins such as E-cadherin and matrix metalloproteinase, which can degrade the ECM components and is believed to play a major role in invasion and metastasis (25) (26) (27) (28) (29) . In support of this, E-cadherin and MMP-2, two Slug target genes, could also be downregulated and upregulated, respectively. Of note, the effect of IK1 on Slug is relatively specific, as Snail1, another member of the Snail family that plays a functional role in ovarian cancer metastasis, was not altered by IK1 overexpression.
One intriguing finding of this study is that IK1 plays a dual role in ovarian cancer cells, inhibiting cell proliferation on one hand and increasing metastatic ability on the other hand. Although apparently conflicting, this kind of phenomenon is not restricted to the Ikaros family. TGF-β signaling has been shown to function as a double-edged sword in ovarian cancer development, a tumor suppressor in early tumorigenesis but a tumor enhancer in advanced-stage cancer (30, 31) . Similar situation may exist for IK1 in the progression of ovarian cancer. In our microarrays study, we found metastatic, poorly differentiated cancer tissues tend to express higher levels of IK1 protein, indicative of the contribution of IK1 in ovarian cancer progression.
In conclusion, we provide evidence that overexpression of IK1 in ovarian cancer cells play a dual role in proliferation, migration and invasion and Slug upregulation contributes to IK1-induced increase of cell migration and invasion. This study reveals a new link between a hematopoietic transcription factor and the metastasis of ovarian cancer cells. Further studies on Ikaros-induced Slug upregulation may provide novel targets for inhibiting ovarian cancer metastasis.
